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Abstract
Individuals diagnosed with colorectal cancer (CRC) are at risk of developing a metachronous 
CRC. We examined the associations between personal, tumour-related and lifestyle risk factors, 
and risk of metachronous CRC. A total of 7,863 participants with incident colon or rectal cancer 
who were recruited in the USA, Canada and Australia to the Colon Cancer Family Registry during 
1997–2012, except those identified as high-risk e.g. Lynch syndrome, were followed up 
approximately every 5 years. We estimated the risk of metachronous CRC, defined as the first new 
primary CRC following an interval of at least one year after the initial CRC diagnosis. Observation 
time started at the age at diagnosis of the initial CRC and ended at the age at diagnosis of the 
metachronous CRC, last contact or death whichever occurred earliest, or were censored at the age 
at diagnosis of any metachronous colorectal adenoma. Cox regression was used to derive hazard 
ratios (HRs) and 95% confidence intervals (CIs). During a mean follow-up of 6.6 years, 142 
(1.81%) metachronous CRCs were diagnosed (mean age at diagnosis 59.8; incidence 2.7/1000 
person-years). An increased risk of metachronous CRC was associated with the presence of a 
synchronous CRC (HR=2.73; 95% CI: 1.30–5.72) and the location of cancer in the proximal colon 
at initial diagnosis (compared with distal colon or rectum, HR=4.16; 95% CI: 2.80–6.18). The 
presence of a synchronous CRC and the location of the initial CRC might be useful for deciding 
the intensity of surveillance colonoscopy for individuals diagnosed with CRC.
Keywords
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Introduction
Individuals diagnosed with a colorectal cancer (CRC) are at increased risk of developing a 
metachronous CRC (a new primary CRC that is not a recurrence or a metastatic deposit of 
the initial lesion) in the remaining part of the large bowel later in life.1 This has been 
reported especially in North America, Europe, Australia and New Zealand, the regions of the 
world with the highest incidence of CRC, where prognosis for individuals affected by an 
initial CRC has improved in recent decades.2 The risk of developing a metachronous CRC in 
the five years following curative surgical resection of the bowel for the initial CRC is around 
2%–12% depending on the intensity of follow-up.3–5
An individual’s risk of developing a metachronous CRC has important clinical implications 
on the extent of the bowel resection for the initial CRC and the frequency of endoscopic 
surveillance of the remaining bowel.6 The extent of the bowel resection, i.e. segmental 
versus extensive, is likely to modify the risk of developing a metachronous CRC because of 
the differences in length of the remaining bowel. This is exemplified by individuals with 
Lynch syndrome whose metachronous CRC risk depends on the type of surgery and the 
length of bowel removed for the initial colon cancer.7 The functional consequence of an 
increase in bowel movement frequency and the possible negative impact on quality of life 
following more extensive surgery need to be balanced against the reduction in the risk of 
metachronous CRC.8 Regardless, surveillance of the remaining colon and rectum is required 
after most surgery (except total proctocolectomy). An initial follow-up colonoscopy is 
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recommended after one year, and if this colonoscopy is clear, the next colonoscopy is 
recommended at three years.6, 9 More intense colonoscopy surveillance (i.e., at shorter 
intervals) is advocated for high-risk individuals6 but the optimal interval for surveillance 
colonoscopy is unclear due to a lack of strong evidence comparing the effectiveness of 
different surveillance regimens and an insufficient understanding of the predictors of 
metachronous CRC risk.
If stratification of individuals based on their risk for metachronous CRC could be made 
routinely, the reduction of metachronous CRC incidence by targeted surveillance 
colonoscopy would become cost-effective.10 Two previous systematic reviews have 
examined risk factors for metachronous colorectal adenoma or cancer6, 11 but have assessed 
only the features of the first diagnosis of CRC or adenoma and not individual’s lifestyle 
factors. In the current study, we used a prospective cohort of adults diagnosed with CRC to 
examine associations between personal, tumour-related features and lifestyle factors and the 
risk of metachronous CRC.
Material and methods
Study sample
Individuals included in the current study were probands diagnosed with incident colon or 
rectal cancer from the Colon Cancer Family Registry. Between 1997 and 2012, they were 
recruited regardless of a family history of cancer via state or regional population cancer 
registries in USA (Washington, California, Arizona, Minnesota, Colorado, New Hampshire, 
North Carolina and Hawaii), Australia (Victoria), and Canada (Ontario) or recruited via 
family cancer clinics in the USA (Mayo Clinic, Rochester, Minnesota, and Cleveland Clinic, 
Cleveland, Ohio), Ontario (Canada), Australia (Melbourne, Adelaide, Perth, Brisbane, 
Sydney) and New Zealand (Auckland).12 Informed consent was obtained from all study 
participants, and the study protocol was approved by the institutional research ethics review 
board at each centre.
Of the 9,916 persons initially identified from the Colon Cancer Family Registry with a CRC 
and who had returned an epidemiologic questionnaire, the following were excluded from 
analysis: those with Lynch syndrome (n=561), monoallelic or biallelic MUTYH mutation 
carriers (n=208), those diagnosed with a cancer of the appendix (n=65), those with total 
resection of colon and rectum (n=5), those with no follow-up (n=105), those with an interval 
of more than 2 years from diagnosis of CRC to enrolment in the study (n=1,100), those who 
had completed baseline data collection questionnaire prior to initial diagnosis (n=8) and 
those missing enrolment date (n=1). None of the remaining 7,863 persons included in this 
analysis had been diagnosed with familial adenomatous polyposis.
Data collection
Data on demographics, race/ethnicity, personal and familial history of cancer, medical 
history, reproduction, diet, alcohol, tobacco, body weight and height were collected via 
standardized personal interviews, telephone interviews and/or mailed questionnaires 
(available at: http://www.coloncfr.org/questionnaires).12 Participants were followed up 
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approximately every 5 years after recruitment into the study to update information across all 
study centres. Reported cancer diagnoses and age at diagnosis were confirmed, where 
possible, using pathology reports, medical records, cancer registry reports and death 
certificates. The anatomic location and histology of the tumours were coded and stored using 
International Classification of Diseases for Oncology, third edition (ICD-O-3).13 Permission 
to access tumour tissue was requested from all participants diagnosed with CRC and blood 
sample from all participants. Vital status, cause of death and date of death were ascertained 
through contact with next-of-kin and/or linkage with population-based registries.
CRC pathology review
CRCs were reviewed by pathologists at each study centre of the Colon Cancer Family 
Registry and assessed for features including histologic grade (low or high grade) and 
synchronous CRCs (present or absent). Low grade was defined as adenocarcinoma with 
≥50% gland formation and high grade as adenocarcinoma with <50% gland formation. 
Diagnosis disease stage was collected from state/provincial cancer registry information 
and/or from clinical/pathology records. When stage data were available both from registries 
and clinical/pathology records, the latter took precedence. Harmonized summary stage data 
were derived according to American Joint Commission on Cancer (AJCC) Tumour Node 
Metastasis (TNM) criteria14 or converted from SEER summary stage to TNM summary 
stage using an algorithm.15 A metachronous CRC was defined as a new primary colon or 
rectal cancer diagnosed at least one year after the first diagnosis of primary colon or rectal 
cancer.
Tumour molecular characterization
Colorectal tumours were characterized for mismatch repair (MMR)-deficiency by 
microsatellite instability (MSI) using a ten-marker panel and/or by immunohistochemistry 
(IHC) for the four MMR proteins. Tumours were classified as MMR-deficient if they were 
MSI-high (≥30% or more of the markers show instability) and/or showed loss of expression 
of one or more of the MMR proteins by IHC; and MMR-proficient if they were 
microsatellite stable (no unstable markers) or MSI-low (<30% unstable markers) and/or 
showed normal expression of all four MMR proteins by IHC.
Statistical analysis
Observation time started at the age at diagnosis of the initial CRC and ended at the age at 
diagnosis of the metachronous CRC (n=142), last contact (n=4,986) or death (n=2,459) 
whichever occurred earliest, or were censored at the age at polypectomy of metachronous 
colorectal adenoma (n=276) given that polypectomy reduces the risk of CRC. In this 
analysis, exposures comprised potential risk factors including demographic, genetic and 
lifestyle characteristics as well as tumour-related features of the initial CRC (listed in Table 
1) and the outcome was the incidence of metachronous CRC. Hazard ratios (HRs) and 95% 
confidence intervals (CIs) were calculated using Cox proportional hazards models to 
estimate the associations between potential risk factors and the risk of metachronous CRC. 
Tests based on Schoenfeld residuals showed no evidence that proportional hazard 
assumptions were violated. Wald tests were used to assess linear trends.
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Frequency of surveillance colonoscopy after surgery for initial CRC, but before the 
diagnosis of metachronous CRC, was estimated from the self-reported questionnaire data. 
The frequency of surveillance colonoscopy was assumed to be distributed uniformly in the 
period between first and last age of colonoscopy.
We devised a multiple imputation model to impute values for missing data that occurred for 
some tumour pathology features, alcohol consumption and interval of surveillance 
colonoscopy. The missing data were assumed to be at random. The model included predictor 
variables, the outcome variable and additional variables that we considered may increase the 
plausibility of the missing at random assumption in order to improve the imputation process. 
We chose 10 sets based on recommendations that the number of sets should approximate the 
percentage of participants with some missing data.16 Alcohol intake was imputed using 
predictive mean matching, stage of first diagnosis of CRC and surveillance colonoscopy 
interval were imputed using ordinal logistic regression, and the other pathology features 
were imputed using logistic regression. Missing values were sampled and replaced with a set 
of plausible values randomly drawn from their predicted distribution based on the other 
observed variables, thus creating 10 completed data sets. Cox proportional hazard regression 
models were run separately for each imputed data set and estimates of the predictor variables 
were combined using the programs written by Carlin et al.17 We compared the estimates of 
association from models using the imputed missing data with the estimates from complete-
case analyses.
A sensitivity analysis was conducted to investigate whether censoring at the age at diagnosis 
of colorectal adenoma changed associations between potential risk factors and metachronous 
CRC risk. All statistical tests were two sided. All statistical analyses were performed using 
Stata 13.1 (StataCorp, College Station, TX).
Results
In this cohort of 7,863 individuals diagnosed with CRC (5,316 colonic; 2,547 rectal), 142 
(1.81%) were diagnosed with a metachronous CRC (mean age 59.8 (standard deviation, SD 
12.7) years at diagnosis; incidence 2.7 per 1000 person-years) during a mean follow-up of 
6.6 (minimum 1; maximum 16) years. Of them, 7,413 (94.3%) were from population-based 
sources and 1,689 (21.5%) had at least one first-degree relative affected with CRC. The 
mean time interval between initial CRC and metachronous CRC diagnoses was 4.1 (SD 3.4) 
years. The cumulative risk of metachronous CRC was 1.59% at 5 years, 2.36% at 10 years, 
and 3.57% at 15 years post-cancer resection (Figure 1A). The initial CRC site was 
approximately equally distributed across the proximal colon (32.6%), distal colon (30.8%) 
and rectum (32.4%), and 329 (4.2%) were coded as unspecified site of the colon. Of the 142 
metachronous CRCs, 51 (35.9%) were located in the proximal colon, 27 (19.1%) in the 
distal colon and 32 (22.5%) in the rectum, and 32 (22.5%) in an unspecified site of the 
colon.
Demographic, lifestyle and tumour features of the initial CRC stratified by cancer site 
(proximal colon, distal colon/rectum, unspecified site of colon) are shown in Table 1. The 
study sample consisted of approximately equal numbers of men and women overall who 
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were predominantly aged 50 years or over and nearly half were never smokers. More than 
one-fifth of the study population had a first-degree family history of CRC. Of individuals for 
whom treatment data were available, 58.0% (n=1,370) reported having chemotherapy while 
33.4% (n = 499) reported having radiation therapy. Of 4,891 CRCs with available tumour 
MMR status, 88% (n=4,327) were MMR-proficient.
The presence of a synchronous CRC at first diagnosis was associated with an increased risk 
of metachronous CRC (HR=2.73; 95% CI: 1.30–5.72) (Table 2; Figure 1B). The proximal 
colon location of the first diagnosis of CRC was associated with a higher risk of 
metachronous CRC (HR=4.16; 95% CI: 2.80–6.18) compared with distal colon or rectum 
(Table 2; Figure 1C). An elevated risk of metachronous CRC associated with a tumour 
MMR-deficiency status in the univariable model was not evident when adjusted for other 
covariates (Table 2). An interval of over 2 years for surveillance colonoscopy was inversely 
associated with the risk of metachronous CRC compared with annual colonoscopy (Table 2). 
There was no evidence for an association between other tumour features, personal features, 
and any of the measured lifestyle factors and the risk of metachronous CRC (Table 2). No 
evidence was found for associations between female reproductive factors (parity, hormonal 
contraceptive use and hormonal replacement therapy) and the risk of metachronous CRC for 
women when included in a multivariable model (details not shown).
In the complete case analysis, the directions of associations were consistent with results 
from the main analysis using imputed data except for diabetes mellitus (Supplementary 
Table 1). Individuals with diabetes mellitus had a higher risk of metachronous CRC than 
those without diabetes (HR=3.77; 95% CI: 1.15–12.3) (Supplementary Table 1). The results 
did not change materially when an analysis was conducted without censoring at the age at 
diagnosis of metachronous colorectal adenoma (Supplementary Table 2).
Discussion
In this prospective cohort study, we observed that the presence of a synchronous CRC and 
the location of the initial CRC in the proximal colon were associated with an increased risk 
of metachronous CRC. There was no evidence for an association between environmental 
factors measured before the initial CRC and the risk of metachronous CRC.
The strengths of the current study include its large sample size, the availability of extensive 
demographic, clinical and lifestyle data, and a substantial follow-up which enabled us to 
examine a wide range of potential risk factors for metachronous CRC. Nonetheless, there 
were some limitations. First, this study lacked detailed data on treatment (including the 
extent of colorectal resection) and complications of treatment which were not able to be 
adjusted for in the multivariable analysis. However, considering the uniformity in treatment 
options for those suitable for surveillance colonoscopy,6 our results may not have changed 
substantially even if treatment data were available. Second, we did not have information on 
the quality of the surveillance colonoscopy as well as the exact timing of the surveillance 
colonoscopy for each individual. Our finding that a longer interval between colonoscopy 
may be inversely associated with the risk of metachronous CRC could be interpreted that 
more frequent surveillance colonoscopy results in greater metachronous CRC detection. 
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Finally, although missing data could potentially have been a limitation, a comprehensive 
imputation procedure was carried out along with a sensitivity analysis comparing risk 
estimates from imputed and complete-case analyses.
The incidence of metachronous CRC occurrence estimated by our analysis was 1.81% (142 
metachronous cancers/7,863 initial cancers) which is closer to the lower end of the range 
reported in the literature (0.6–9%).18 These estimates could be affected by the length of 
survival and length of follow-up. Similar to our finding, previous studies that examined 
tumour location as a risk factor observed that the initial cancer in the proximal colon is 
associated with a higher risk of metachronous CRC.19, 20 The 2.2% prevalence of 
synchronous CRC in our cohort was comparable with 2–7% reported elsewhere.3, 21 Our 
finding of the presence of synchronous CRC being a risk factor for metachronous CRC is 
also consistent with the previous reports.3, 18, 22
Chromosomal instability (CIN), MSI, and CpG island methylator phenotype (CIMP) are the 
three molecular pathways explaining the pathogenesis of CRC.23 Arain et al.24 reported that 
interval cancers in the colon were 2.5-times more likely to demonstrate CIMP, were 2.7-
times more likely to demonstrate MSI, and also had a 2-fold higher incidence in the 
proximal colon. Similarly, in a study using data from the Nurses’ Health Study and the 
Health Professionals Follow-up Study, Nishihara et al. found that CRC diagnosed within 5 
years after screening colonoscopy was more likely to be characterized by CIMP, MSI and 
high-level LINE-1 methylation than cancer diagnosed more than 5 years after 
colonoscopy.25 While evidence is still lacking that the CIMP pathway could independently 
play a role in accelerated tumour growth, our evidence of a greater risk of metachronous 
cancer for individuals with an initial cancer in the proximal colon could well be related to 
CIMP-related interval cancers. We were not able to stratify our analysis by tumour site (e.g. 
initial cancer in the proximal colon and metachronous cancer in the distal colon/rectum) due 
to the relatively small number of metachronous CRCs available by anatomical site (51 in the 
proximal colon, 59 in the distal colon/rectum).
Identification and removal of adenomatous polyps through surveillance colonoscopy reduce 
the risk of metachronous CRC.6 The clinical guidelines suggest surveillance colonoscopies 
at intervals of 1, 3 and 5 years if the findings continue to be normal.6 Our findings suggest 
that individuals diagnosed with a CRC in the proximal colon and those with a synchronous 
CRC might be considered for more intense surveillance colonoscopy.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Novelty and Impact
The location of the initial colorectal cancer in the proximal colon and the presence of a 
synchronous colorectal cancer were associated with an increased risk of metachronous 
colorectal cancer thus highlighting their important when deciding on the intensity of 
surveillance colonoscopy whereas personal, lifestyle factors and female reproductive 
factors were not associated.
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Figure 1. 
Nelson–Aalen estimate of the cumulative hazard rate function for incidence of 
metachronous colorectal cancer for individuals with colorectal cancer. A, overall (solid), 
95% confidence limits (dashed); B, synchronous colorectal cancer present (solid), 
synchronous colorectal cancer absent (dashed); C, proximal colon (solid), distal colon/
rectum (black dashed), unspecified colon (gray dashed).
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Table 1
Baseline Characteristics of Individuals with Colorectal Cancer (CRC): Colon Cancer Family Registry, 1997 to 
2012
Initial cancer sitea Total(n=7,863)
Proximal colon
(n=2562)
Distal colon/rectum
(n=4,972)
Unspecified colon
(n=329)
n (%) n (%) n (%) n (%)
Age at initial diagnosis, years
 <50 741 (28.9) 2,117 (42.6) 132 (40.1) 2,990 (38.0)
 ≥50 1,821 (71.1) 2,855 (57.4) 197 (59.9) 4,873 (62.0)
 Mean age (years) 58.0 53.9 54.9 55.3
Colon Cancer Family Registry site
 Cancer Care Ontario, Toronto, Canada 615 (24.0) 1,287 (25.9) 37 (11.3) 1,939 (24.7)
 University of Southern California Consortium 572 (22.3) 875 (17.6) 230 (69.9) 1,677 (21.3)
 University of Melbourne, Australia 228 (8.9) 568 (11.4) 10 (3.0) 806 (10.2)
 University of Hawaii, Honolulu, HI 142 (5.5) 303 (6.1) 1 (0.3) 446 (5.7)
 Mayo Clinic, Rochester, MN 168 (6.7) 424 (8.5) 16 (4.9) 608 (7.7)
 Fred Hutchinson Cancer Research Center 767 (29.9) 1,420 (28.6) 29 (8.8) 2,216 (28.2)
 Cancer Prevention Institute of California 70 (2.7) 95 (1.9) 6 (1.8) 171 (2.2)
Source of ascertainment
 Population-based 2,407 (93.9) 4,699 (94.5) 307 (93.3) 7,413 (94.3)
 Clinic-based 155 (6.1) 273 (5.5) 22 (6.7) 450 (5.7)
Sex
 Male 1,167 (45.5) 2,633 (53.0) 169 (51.4) 3,969 (50.5)
 Female 1,395 (54.5) 2,339 (47.0) 160 (48.6) 3,894 (49.5)
First-degree family history of CRC
 No 1,948 (76.0) 3,970 (79.9) 256 (77.8) 6,174 (78.5)
 Yes 614 (24.0) 1,002 (20.1) 73 (22.2) 1,689 (21.5)
Cigarette smoking statusb
 Never 1,164 (45.4) 2,194 (44.1) 164 (49.8) 3,522 (44.8)
 Former 1,121 (43.8) 2,212 (44.5) 126 (38.3) 3,459 (44.0)
 Current 277 (10.8) 566 (11.4) 39 (11.9) 882 (11.2)
Alcohol intake
 Abstainer 813 (31.7) 1,299 (26.1) 105 (31.9) 2,217 (28.2)
 <1 drink/day 505 (19.7) 1,097 (22.1) 54 (16.4) 1,656 (21.1)
 1–<2 drinks/day 251 (9.8) 517 (10.4) 30 (9.1) 798 (10.1)
 2–<3 drinks/day 79 (3.1) 279 (5.6) 17 (5.2) 375 (4.8)
 ≥3 drinks/day 182 (7.1) 491 (9.9) 42 (12.8) 715 (9.1)
 Missing 732 (28.6) 1,289 (25.9) 81 (24.6) 2,102 (26.7)
BMI recentc, kg/m2
 <18.5 61 (2.4) 150 (3.0) 27 (8.2 238 (3.0)
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Initial cancer sitea Total(n=7,863)
Proximal colon
(n=2562)
Distal colon/rectum
(n=4,972)
Unspecified colon
(n=329)
n (%) n (%) n (%) n (%)
 18.5–<25 900 (35.1) 1,687 (33.9) 117 (35.6) 2,704 (34.4)
 25–<30 928 (36.2) 1,844 (37.1) 106 (32.2) 2,878 (36.6)
 ≥30 673 (26.3) 1,291 (26.0) 79 (24.0) 2,043 (26.0)
BMI at age 20 yearsd, kg/m2
 <18.5 313 (12.2) 467 (9.4) 94 (28.6) 874 (11.1)
 18.5–<25 1,671 (65.2) 3,340 (67.2) 175 (53.2) 5,186 (66.0)
 25–<30 418 (16.3) 821 (16.5) 39 (11.8) 1,278 (16.2)
 ≥30 160 (6.3) 344 (6.9) 21 (6.4) 525 (6.7)
Diabetes mellituse
 No 2,197 (85.7) 4,416 (88.8) 270 (82.1) 6,883 (87.5)
 Yes 365 (14.3) 556 (11.2) 59 (17.9) 980 (12.5)
Aspirin intake
 No 1,739 (67.9) 3,664 (73.7) 237 (72.0) 5,640 (71.7)
 Yes 823 (32.1) 1,308 (26.3) 92 (28.0) 2,223 (28.3)
Ibuprofen intake
 No 2,156 (84.1) 4,150 (83.5) 286 (86.9) 6,592 (83.8)
 Yes 406 (15.9) 822 (16.5) 43 (13.1) 1,271 (16.2)
Multivitamin supplement intake
 No 1,216 (47.5) 2,481 (49.9) 152 (46.2) 3,849 (49.0)
 Yes 1,346 (52.5) 2,491 (50.1) 177 (53.8) 4,014 (51.0)
Calcium supplement intake
 No 1,848 (72.1) 3,775 (75.9) 261 (79.3) 5,884 (74.8)
 Yes 714 (27.9) 1,197 (24.1) 68 (20.7) 1,979 (25.2)
Parityf
 0 165 (11.8) 274 (11.7) 20 (12.5) 459 (11.8)
 1–2 441 (31.6) 804 (34.4) 57 (35.6) 1,302 (33.4)
 ≥3 789 (56.6) 1,261 (53.9) 83 (51.9) 2,133 (54.8)
Hormonal contraceptive use for at least 1 yearf
 No 641 (46.0) 903 (38.6) 73 (45.6) 1,617 (41.5)
 Yes 754 (54.0) 1,436 (61.4) 87 (54.4) 2,277 (58.5)
Use of hormonal replacement therapy for at least 6 monthsg
 No 567 (54.1) 901 (58.6) 79 (69.3) 1,547 (57.3)
 Yes 481 (45.9) 637 (41.4) 35 (30.7) 1,153 (42.7)
Surveillance colonoscopy intervalh
 ≤1 year 94 (3.7) 180 (3.6) 13 (3.9) 287 (3.6)
 >1–2 years 327 (12.8) 726 (14.6) 47 (14.3) 1,100 (14.0)
 >2–3 years 261 (10.2) 525 (10.6) 26 (7.9) 812 (10.3)
 >3 years 594 (23.2) 1,126 (22.6) 46 (14.0) 1,766 (22.5)
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Initial cancer sitea Total(n=7,863)
Proximal colon
(n=2562)
Distal colon/rectum
(n=4,972)
Unspecified colon
(n=329)
n (%) n (%) n (%) n (%)
 No colonoscopy 32 (1.2) 48 (1.0) 0 (0.0) 80 (1.0)
 Missing 1,254 (48.9) 2,367(47.6) 197 (59.9) 3,818 (48.6)
Synchronous CRC
 No 1,921 (75.0) 3,798 (76.4) 174 (52.9) 5,893 (75.0)
 Yes 91 (3.5) 77 (1.5) 6 (1.8) 174 (2.2)
 Missing 550 (21.5) 1,097 (22.1) 149 (45.3) 1,796 (22.8)
Synchronous adenoma
 No 1,031 (40.2) 1,966 (39.5) 75 (22.8) 3,072 (39.1)
 Yes 359 (14.0) 794 (16.0) 40 (12.2) 1,193 (15.2)
 Missing 1,172 (45.8) 2,212 (44.5) 214 (65.0) 3,598 (45.7)
TNM stage
 I 204 (8.0) 523 (10.5) 10 (3.0) 737 (9.4)
 II 297 (11.6) 378 (7.6) 6 (1.8) 681 (8.7)
 III 323 (12.6) 544 (10.9) 8 (2.4) 875 (11.1)
 IV 148 (5.8) 268 (5.4) 21 (6.4) 437 (5.6)
 Missing 1,590 (62.1) 3,259 (65.6) 284 (86.3) 5,133 (65.3)
Tumour grade
 Low 1,300 (50.7) 2,936 (59.0) 91 (27.7) 4,327 (55.0)
 High 427 (16.7) 476 (9.6) 22 (6.7) 925 (11.8)
 Missing 835 (32.6) 1,560 (31.4) 216 (65.6) 2,611 (33.2)
Tumour mismatch repair status
 Proficient 1,197 (46.7) 3,059 (61.5) 52 (15.8) 4,308 (54.8)
 Deficient 442 (17.3) 137 (2.8) 4 (1.2) 583 (7.4)
 Missing 923 (36.0) 1,776 (35.7) 273 (83.0) 2,972 (37.8)
Chemotherapy
 Yes 412 (16.1) 945 (19.0) 13 (3.9) 1,370 (17.4)
 No 337 (13.1) 643 (12.9) 12 (3.7) 992 (12.6)
 Missing 1,813 (70.8) 3,384 (68.1) 304 (92.4) 5,501 (70.0)
Radiotherapy
 Yes 16 (0.6) 479 (9.6) 4 (1.2) 499 (6.3)
 No 409 (16.0) 572 (11.5) 16 (4.9) 997 (12.7)
 Missing 2,137 (83.4) 3,921 (78.9) 309 (93.9) 6,367 (81.0)
aAccording to International Classification of Diseases for Oncology, Third Edition anatomical site codes: C18.0, C18.2, C18.3, C18.4 (proximal 
colon); C18.5, C18.6, C18.7, C19.9, C20.9 (distal colon/rectum); C18.8, C18.9, C26.0 (unspecified colon).
bCigarette smoking was defined as ever smoking one cigarette per day for 3 months or longer. Current smoking was indicated when persons 
reported smoking in the referent period (defined as two years prior to enrolment); former smoking was indicated when persons stopped smoking 
before the referent period.
c
Derived from pre-diagnosis recent body weight (defined as “weight 2 years prior to enrolment”) in kg divided by height in meters squared.
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d
Derived from body weight at age 20 years in kg divided by height in meters squared.
eSelf-report that diabetes mellitus was diagnosed by a physician, excluding gestational diabetes.
fNumbers add up to women.
gNumbers add up to menopausal women.
h
Derived from time since initial colorectal cancer diagnosis divided by number of post-diagnosis surveillance colonoscopies.
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